IP Library Granted Patent US 9,623,092
Granted Patent B2
US 9,623,092 · App. 13/912,077 · Granted Apr 18, 2017

Treatment of gluten intolerance and related conditions

Inventor: David Schriemer (Chestermere, CA)
Assignee: NEPETX, LLC
A61K38/488A23L29/06A23L33/10A23L33/105C12Y304/23012A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,623,092
App. No.
13/912,077
Granted
Apr 18, 2017
Kind
B2
Abstract

Provided herein are compositions, foods comprising nepenthesin or a derivative thereof and methods of using nepenthesin or a derivative thereof for modulating gluten intolerance and related conditions, such as celiac disease.

Claims (11)

1. A solid composition for treating or attenuating gluten intolerance comprising:

(a) an effective amount of nepenthesin selected from the group consisting of a nepenthesin I salt, a nepenthesin II salt, or a combination thereof, and

(b) an effective amount of a buffer to maintain the pH of said solid composition at a pH of 5 or above, wherein said nepenthesin is inactive prior to administration;

wherein said effective amount of nepenthesin is sufficient to degrade gluten upon oral administration of said solid composition to a patient suffering from gluten intolerance.

2. The solid composition of claim 1 , wherein said effective amount of nepenthesin is between about 1 mg and about 1 g, wherein about refers to a variation of up to ±5%.

3. The solid composition of claim 1 , further comprising at least one additional agent selected from the group consisting of an inhibitor of a transglutaminase, an anti-inflammatory agent, a COX-2 inhibitor, a p38 MAP kinase inhibitor, a mast cell-stabilizing agent, an anti-ulcer agent, an anti-allergy agent, and an anti-TNF-α agent.

4. The solid composition of claim 1 , further comprising at least one additional enzyme selected from the group consisting of a gastric protease, an aspartic protease, and a prolyl endopeptidase.

5. The solid composition of claim 1 , wherein said composition is formulated to release said nepenthesin in a patient's stomach.

6. The solid composition of claim 2 , wherein said effective amount of said nepenthesin is between about 1 mg and about 500 mg.

7. The solid composition of claim 2 , wherein said effective amount of said nepenthesin is between about 1 mg and about 200 mg.

8. The solid composition of claim 1 , wherein said gluten intolerance is celiac disease, wheat allergy, gluten sensitivity, or dermatitis herpetiformis.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: CODEXIS, INC.
Reel/Frame 069789/0740 →
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 1, 2020
From: NEPETX, LLC
To: CODEXIS, INC.
Reel/Frame 052804/0249 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2014
From: SCHRIEMER, DAVID C.
To: NEPETX, LLC
Reel/Frame 033875/0852 →
Continuity (3)
Provisional Application 61729210 · Nov 21, 2012
Provisional Application 61797040 · Nov 27, 2012
Related Publication 20140140980A1 · May 22, 2014